Brain bleed drug doses under scrutiny: could one size fit all be wrong?

NCT ID NCT07065903

First seen Feb 10, 2026 · Last updated May 13, 2026 · Updated 10 times

Summary

This study looks at how much of the drug nimodipine gets into the blood of people who have had a bleeding brain aneurysm. The goal is to see if different levels of the drug affect recovery and disability 90 days later. Researchers will study 500 adults in Canada and the USA to find out if the standard dose works for everyone or if personalized dosing could improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SUBARACHNOID HEMORRHAGE, ANEURYSMAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Health Network - Toronto Western Hospital

    RECRUITING

    Toronto, Ontario, M5T 2S8, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Alberta Hospital

    RECRUITING

    Edmonton, Alberta, T6G 2X8, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • VCU Medical Center

    RECRUITING

    Richmond, Virginia, 23219, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.